Georgia Start-Up Gets Federal Funding for Nasal COVID Vaccine Trial

A University of Georgia-based start-up, CyanVac LLC, announces it will commence a clinical trial for a nasal COVID-19 vaccine this fall, bolstered by federal funding. The innovative trial is funded by Project NextGen, a federal initiative managed by the U.S. Department of Health and Human Services aimed at advancing next-generation COVID-19 vaccines and treatments.

A University of Georgia-based start-up will launch a nasal COVID vaccine trial this fall. Sara Lee Kessler reports.

The new vaccine utilizes a unique viral delivery platform that incorporates modified strains of canine influenza virus, which. . .